Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. – 11:00 a.m. ET Abstract Number: 3107 The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on meetings.asco.org . About Tempest Therapeutics Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com . Investor Contacts: Sylvia Wheeler Wheelhouse Life Science Advisors [email protected] Aljanae Reynolds Wheelhouse Life Science Advisors [email protected] 1 If approved by the FDA © 2026 Tempest Therapeutics. All rights reserved. var s_CCSWebHostingAccount = "trcgtempesttherapeutics"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9616","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkeFuQyEIhV-ouTbN3oegstZdhRug2_r2tbqk7bJliz8U_ORwkIsCMtaLl2SBH6MFs0SCimdOpx3_CW4qeWARjQZRkrA9p1ykRtSRTCvl4qKQ0fuKlSzcj8urCjvxrNlQV_JBQqyS1jDkzUHRCx-7Qi94QvV_4QZD5Be2ETIoJWmt6_cHwo-1z9VL661jeA7H7YbH6fR2WPANPwFzhlTRDLCSuv3ApWHVwS6cuhVmmiPaSn45HPZB3km15NnwB0UrTsDSp0_zM77llq99Z90ztXCb_xUmCsI1","theme":"nir_pid4220","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"e4cd9886b98324d3a81033a7e8a58e5b662d9828a13ae2363f42a309d045dd8e"}}

The release as fetched from its publisher. tempesttx.com ↗